S-Adenosylhomocysteine (SAH) Monoclonal Antibody for Cardiovascular Risk CLIA IVD Development
S-Adenosylhomocysteine (SAH) is the direct metabolic by-product of SAM (S-adenosylmethionine)-dependent transmethylation reactions. When SAM donates its methyl group to a biological substrate — DNA, RNA, proteins, or lipids — it is converted to SAH (molecular weight 384 Da). SAH is subsequently hydrolyzed by the enzyme SAH hydrolase (SAHH) into adenosine and homocysteine (Hcy). Critically, the SAH/SAM ratio — often called the "methylation index" — provides a direct, quantitative measure of cellular methylation capacity. Elevated SAH inhibits SAHH, creating a feedback loop that impairs global methylation and promotes hyperhomocysteinemia.
From a cardiovascular risk perspective, SAH is increasingly recognized as a superior biomarker compared to homocysteine (Hcy) alone. While elevated Hcy is an established independent risk factor for cardiovascular disease, SAH elevation more sensitively reflects underlying methylation abnormalities and vascular endothelial dysfunction that precede overt Hcy elevation. Elevated plasma SAH is directly associated with atherosclerosis progression, myocardial infarction risk, and chronic kidney disease (CKD)-related cardiovascular complications. Clinical research in China, Japan, and South Korea has demonstrated that SAH is a clinically actionable methylation biomarker, with SAH testing complementing or even outperforming Hcy alone in risk stratification. The SAH CLIA market is emerging in East Asia and expanding into European cardiovascular diagnostics.
For IVD assay development, SAH presents a unique challenge: at 384 Da, it is a small molecule that cannot accommodate simultaneous binding of two antibodies (sandwich format). Competitive immunoassay (competitive CLIA, competitive ELISA) is therefore the mandatory detection format. This requires an antibody with the highest possible affinity to achieve picomolar-range sensitivity. Sekbio SAH-302 anti-SAH monoclonal antibody delivers an exceptional affinity of Ka=4.2×10⁸ L/mol (Kd=2.38 nM), ensuring reliable detection of SAH at physiologically relevant low concentrations in plasma. The companion product S01-SAHBSA-1w (SAH-BSA conjugate) provides the immobilized coating antigen essential for competitive CLIA and competitive ELISA platform development. Together, these two products provide the complete antibody raw material set required to build a SAH competitive immunoassay from R&D to OEM production.
One anti-SAH monoclonal antibody and one SAH-BSA coating conjugate for complete competitive CLIA and ELISA immunoassay development.
| Catalog No. | Product Name | Type | Purity | Intended Use | Storage |
|---|---|---|---|---|---|
| SAH-302 | Mouse Anti-SAH Monoclonal Antibody (IgG1) | Antibody | >90% SEC-HPLC | Competitive CLIA / LFA / ELISA — Detection Antibody | +2°C to +8°C |
| S01-SAHBSA-1w | SAH-BSA Conjugate (Coating Antigen) | Conjugate | >90% SEC-HPLC | Competitive CLIA / ELISA — Coating Antigen | +2°C to +8°C |
Both products supplied in 20 mM PB, 150 mM NaCl, pH 7.4. MOQ 1 mg. OEM quantities available. Contact info@sekbio.com for bulk pricing and technical development support.
Engineered for the picomolar sensitivity and competitive format precision required in cardiovascular SAH CLIA diagnostics.
SAH-302 anti-SAH antibody achieves a binding affinity of Ka=4.2×10⁸ L/mol (Kd=2.38 nM), measured by competitive binding assay. In competitive immunoassay formats, antibody affinity is the primary determinant of assay sensitivity and lower limit of detection. Sub-nanomolar Kd ensures reliable SAH detection at clinically relevant picomolar plasma concentrations.
SAH (MW 384 Da) is too small for sandwich immunoassay. SAH-302 is specifically optimized for competitive CLIA and competitive ELISA — the technically correct and only feasible format for small-molecule detection. The antibody's epitope selectivity ensures minimal cross-reactivity with structurally similar molecules such as SAM, adenosine, or homocysteine.
Sekbio provides both SAH-302 antibody and S01-SAHBSA-1w (SAH-BSA conjugate coating antigen) as a matched development set. The BSA conjugate is optimized for ELISA plate or CLIA microparticle coating, eliminating the need for in-house conjugation and accelerating assay development timelines from months to weeks.
Both SAH-302 and S01-SAHBSA-1w are manufactured under ISO 13485 Quality Management System in Shenzhen, China. Each lot undergoes appearance, purity by SEC-HPLC (>90%), and competitive binding activity QC before release. Full Certificate of Analysis provided with every shipment, supporting CE-marked IVD kit dossier documentation requirements.
SAH competitive CLIA is an emerging cardiovascular risk testing category with active clinical adoption in China, Japan, and South Korea, and growing interest in European cardiovascular reference laboratories. IVD manufacturers entering the SAH testing market now can establish clinical partnerships before the market matures. Sekbio provides both the antibody raw materials and technical support for assay development.
MOQ 1 mg for R&D evaluation; gram-scale OEM production quantities available. Sekbio's ISO 13485-compliant Shenzhen manufacturing facility supports scalable production for both pilot and commercial-stage IVD kit manufacturing. Competitive pricing for mid-to-large volume OEM orders. Global shipping with proper cold-chain logistics to Europe, North America, and Asia-Pacific.
SAH competitive immunoassay antibodies validated for cardiovascular risk assessment, methylation monitoring, and research diagnostics kit development.
Elevated plasma SAH is directly associated with atherosclerosis, endothelial dysfunction, and myocardial infarction risk. SAH elevation occurs earlier in the methylation dysregulation cascade than Hcy elevation alone, making it a sensitive early cardiovascular risk indicator. SAH competitive CLIA kits — built on SAH-302 antibody — enable hospital cardiology laboratories to add SAH testing to cardiovascular risk panels alongside Hcy, CRP, and lipid profiles. This is especially relevant in East Asian clinical markets where methylation biomarker testing is actively incorporated into cardiovascular risk assessment protocols.
CKD patients exhibit significantly elevated plasma SAH due to impaired renal clearance of homocysteine precursors and reduced SAHH activity. SAH elevation in CKD is a marker of methylation insufficiency and correlates with CKD progression severity and cardiovascular event risk. SAH competitive CLIA assays enable nephrologists to monitor methylation status in CKD patients, complement eGFR and proteinuria testing, and stratify cardiovascular risk in the CKD population. SAH-302-based assay kits support CKD nephrology departments and renal dialysis unit monitoring programs.
Patients with elevated total homocysteine (tHcy) benefit from combined SAH and SAM measurement to characterize the underlying methylation defect. The SAH/SAM ratio (methylation index) reveals whether hyperhomocysteinemia is driven by methylation pathway impairment (elevated SAH, reduced SAM) or by cystathionine pathway insufficiency. SAH CLIA kits enable clinical biochemistry laboratories to provide a complete one-carbon metabolism panel — tHcy, SAH, and SAM — for precise diagnosis of methylation disorders, vitamin B12 and folate deficiency, and MTHFR polymorphism-related hyperhomocysteinemia.
SAH-302 and S01-SAHBSA-1w are also suited for research-use-only (RUO) ELISA kit development for academic and pharmaceutical research into epigenetics, methylation biology, and cardiovascular disease mechanisms. Research groups studying DNA methylation, histone methylation, or one-carbon metabolism can use Sekbio's SAH antibody and conjugate to develop quantitative competitive ELISA assays for cell culture supernatants, tissue lysates, and animal plasma. Contact our team or visit our platforms page for antibody development and custom conjugation services.
Technical and commercial questions from IVD R&D engineers and procurement teams developing SAH competitive immunoassays.
SAH (S-adenosylhomocysteine, MW 384 Da) is the immediate metabolic by-product of SAM-dependent methylation reactions. It is hydrolyzed by SAHH into adenosine and homocysteine. The SAH/SAM ratio is a direct measure of cellular methylation capacity (methylation index). Elevated plasma SAH is associated with cardiovascular disease, atherosclerosis, and endothelial dysfunction. SAH is a more sensitive cardiovascular risk biomarker than homocysteine alone in many clinical contexts, particularly in Asian populations with methylation metabolism research emphasis.
Sekbio supplies: SAH-302 (Mouse anti-SAH mAb, IgG1, affinity-purified, >90% SEC-HPLC, Ka=4.2×10⁸ L/mol / Kd=2.38 nM, competitive CLIA/LFA/ELISA) and S01-SAHBSA-1w (SAH-BSA conjugate, >90% SEC-HPLC, coating antigen for competitive assay). Both available from MOQ 1 mg with full Certificate of Analysis.
SAH has a molecular weight of only 384 Da. Sandwich immunoassays require two antibodies binding simultaneously to different epitopes on the same analyte molecule — physically impossible for analytes below ~1,000 Da. Competitive immunoassay (sample SAH competes with labeled SAH-conjugate for limited antibody binding sites) is the only viable detection format. SAH-302 is optimized for competitive CLIA and ELISA; S01-SAHBSA-1w provides the BSA-conjugated coating antigen required for this format.
SAH-302 has a binding affinity of Ka=4.2×10⁸ L/mol (Kd=2.38 nM). In competitive immunoassays, antibody affinity is the primary driver of assay sensitivity — higher affinity directly translates to lower limit of detection and wider working range at low analyte concentrations. The sub-nanomolar Kd of SAH-302 ensures accurate SAH detection at the picomolar plasma concentrations relevant to clinical cardiovascular risk assessment, which is critical for distinguishing subtle methylation changes in at-risk patient populations.
MOQ is 1 mg for R&D evaluation; OEM quantities available on request. Storage for both products: +2°C to +8°C. Supplied in 20 mM PB, 150 mM NaCl, pH 7.4. Avoid repeated freeze/thaw cycles. Full Certificate of Analysis with each lot. Contact info@sekbio.com for bulk pricing and OEM supply agreements.
Yes. Sekbio provides both SAH-302 antibody and S01-SAHBSA-1w coating antigen for OEM competitive CLIA kit manufacturing. Our ISO 13485-certified manufacturing in Shenzhen delivers consistent batch-to-batch performance for CE-marked IVD kit production. Technical development support, application notes, and assay development consultation are available. Contact info@sekbio.com to discuss SAH competitive CLIA kit development, OEM supply volumes, and regulatory documentation support.
Request the full technical datasheet, competitive assay development guide, or discuss OEM supply with our team.